Genenta Science S.p.A. (GNTA)

NASDAQ: GNTA · Delayed Price · USD
9.32
-0.55 (-5.53%)
At close: Jan 24, 2022 4:00 PM
9.25
-0.07 (-0.71%)
After-hours:Jan 24, 2022 4:00 PM EST
Market Cap169.12M
Revenue (ttm)n/a
Net Income (ttm)-8.30M
Shares Out18.15M
EPS (ttm)-0.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,423
Openn/a
Previous Close9.86
Day's Range8.28 - 9.85
52-Week Range8.28 - 13.13
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About GNTA

Genenta Science is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. We have developed a novel biologic platform which involves the ex-vivo gene transfer of a therapeutic candidate into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Our technology is designed to turn TEMs, which normally have an affinity for and t...

IndustryBiotechnology
IPO DateDec 15, 2021
CEOPierluigi Paracchi
Employees4
Stock ExchangeNASDAQ
Ticker SymbolGNTA
Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

News

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cel...

1 month ago - GlobeNewsWire

Genenta Announces Pricing of Upsized Initial Public Offering

MILAN, Italy and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A., a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene t...

1 month ago - GlobeNewsWire